uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
CMV disease in CMV-mismatched renal transplant recipients with prophylactic low dose valaciclovir
Uppsala University, Medicinska vetenskapsområdet, Faculty of Medicine, Department of Medical Sciences.
2001 In: Journal of Clinical Virology, ISSN 1386-6532, no 23, 107-111 p.Article in journal (Refereed) Published
Place, publisher, year, edition, pages
2001. no 23, 107-111 p.
URN: urn:nbn:se:uu:diva-97641OAI: oai:DiVA.org:uu-97641DiVA: diva2:172662
Available from: 2008-10-29 Created: 2008-10-29Bibliographically approved
In thesis
1. Cytomegalovirus Infection in Immunocompetent and Renal Transplant Patients: Clinical Aspects and T-cell Specific Immunity
Open this publication in new window or tab >>Cytomegalovirus Infection in Immunocompetent and Renal Transplant Patients: Clinical Aspects and T-cell Specific Immunity
2008 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Cytomegalovirus (CMV) is a β-herpesvirus that, after primary infection, establishes a life-long persistence in the human host. Up to 90% of humans are infected with CMV, that is kept under control by CMV-specific CD8+ and CD4+ T cells. In patients with an impaired cellular immunity, however, CMV infections can be life-threatening. Thus, it is vital to identify risk factors and target high-risk patients. In this thesis we have evaluated low-dose valacyclovir prophylaxis in renal transplant patients and studied CMV-specific T cell immunity in healthy and renal transplant patients.

In renal transplant patients, the CMV serostatus of both the recipient (R) and the donor (D) has a major impact on the risk of developing CMV disease. In the high-risk D+/R- population, >50% are likely to develop CMV disease in the absence of prophylaxis and/or pre-emptive therapy. We have used low-dose valacyclovir prophylaxis for high-risk renal transplant patients, and graft and patient survival up to 5 years after transplantation was comparable to data reported for other prophylactic protocols. The incidence of CMV disease and graft rejection during the first year after transplantation was also comparable to that achieved with other protocols, and without the adverse effects reported for other therapies.

In the D+/R+ population, with a 15-35% risk of developing CMV disease, it is important to identify those individuals that are subject to a higher risk because of risk factors other than CMV serostatus. We therefore measured several immunologic parameters in renal transplant patients and in immunocompetent individuals with latent and primary CMV infection. In patients with a primary symptomatic CMV infection, CMV-specific CD8+ T cells peaked within a month after onset of symptoms but declined rapidly. In renal transplant patients, we found that the reduction in IFNγ-producing CMV-specific CD4+ T cells at 2 months post-transplantation may predict high-grade CMV DNAemia.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2008. 87 p.
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206 ; 386
Cytomegalovirus, renal transplantation, cellular immunity, valacyclovir, mismatched, prophylaxis, tetramer, CD4 T cells, CD8 T cells
National Category
Infectious Medicine
urn:nbn:se:uu:diva-9324 (URN)978-91-554-7309-9 (ISBN)
Public defence
2008-11-29, Rudbecksalen, Rudbecklaboratoriet, Dag Hammarskjölds väg 20, Uppsala, 09:15
Available from: 2008-10-29 Created: 2008-10-29 Last updated: 2010-12-28Bibliographically approved

Open Access in DiVA

No full text

By organisation
Department of Medical Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 145 hits
ReferencesLink to record
Permanent link

Direct link